BHF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Brighthouse Financial is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a mildly constructive moving-average structure, but momentum is weak, recent earnings quality is poor, and there is no strong proprietary buy signal. My direct view: hold for now rather than buy immediately.
BHF is trading near 61.67, just below the pivot at 62.176 and close to support at 61.605. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), which supports the broader trend, but MACD histogram is negative and expanding, showing short-term momentum deterioration. RSI_6 at 33.4 is near oversold territory but not a clean reversal signal. Overall, the technical picture is mixed: long-term trend is okay, but near-term strength is fading and price is sitting close to support rather than breaking out.
["Bullish moving-average alignment (SMA_5 > SMA_20 > SMA_200)", "Options volume shows stronger call activity than put activity today", "Keefe Bruyette set a $67 price target, above the current price", "Longer-term candlestick pattern statistics suggest a positive one-month tendency (+8.18%)"]
["MACD is negative and worsening, signaling short-term downside pressure", "Latest quarter net income and EPS both fell sharply year over year", "No recent news catalysts in the past week", "No meaningful hedge fund or insider buying trend", "No recent congress trading data", "Analyst rating is only Market Perform, not bullish"]
In 2025/Q4, revenue rose 40.17% year over year to $1.689 billion, which is a strong top-line increase. However, profitability weakened materially: net income fell 82.66% YoY to $112 million and EPS dropped 81.73% YoY to $1.94. That means growth in revenue did not translate into earnings strength this quarter. For a beginner long-term investor, the earnings decline is the more important signal than the revenue growth.
Keefe Bruyette re-initiated coverage on 2026-03-26 with a Market Perform rating and a $67 price target. This is a neutral stance, with limited upside from current levels. The firm noted the life insurance sector has improved in some areas, but also faces intensifying competition, greater leverage, balance sheet complexity, and fading macro tailwinds. Wall Street’s pros view is that the sector has improved structurally; the cons view is that competition and leverage can limit re-rating potential. Overall sentiment from analysts is cautious rather than bullish.
